Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.5.1.2
Substance Class Protein
Protein Sub Type
Sequence Type COMPLETE
Record UNII
7J9Y28299R
Record Status Validated (UNII)
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details References
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2
Common Name
English  
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
Common Name
English  
CD340
Common Name
English  
NEU
Common Name
English  
METASTATIC LYMPH NODE GENE 19 PROTEIN
Common Name
English  
NGL
Common Name
English  
TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER2
Common Name
English  
PROTO-ONCOGENE NEU
Common Name
English  
HER2/NEU
Common Name
English  
ERBB2
Common Name
English  
P185ERBB2
Common Name
English  
HER-2
Common Name
English  
HER2
Common Name
English  
PROTO-ONCOGENE C-ERBB-2
Common Name
English  
MLN19
Common Name
English  
ERBB-2
Common Name
English  
Code System Code Type Description References
WIKIPEDIA
HER2/neu
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
PRIMARY
UNIPROT
P04626
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
PRIMARY
From To
1_4 1_31
1_140 1_170
1_173 1_182
1_177 1_190
1_198 1_205
1_202 1_213
1_214 1_222
1_218 1_230
1_233 1_242
1_246 1_273
1_277 1_289
1_293 1_309
1_312 1_316
1_320 1_345
1_453 1_482
1_489 1_498
1_493 1_506
1_509 1_518
1_522 1_538
1_541 1_554
1_545 1_562
1_565 1_574
1_578 1_601
1_604 1_612
1_608 1_620
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_46
N 1_102
N 1_165
N 1_237
N 1_508
N 1_549
N 1_607
Related Record Type Details References
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
Mediator Substance Details
none
BINDING
HER dimerization inhibitor
Created by admin on Fri Jul 10 18:35:32 EDT 2020 , Edited by admin on Fri Jul 10 18:35:32 EDT 2020
INHIBITOR -> TARGET
none
Mediator Substance Details
none
IgG1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity targeting HER2 and HER3 receptors.
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
LIGAND->TARGET
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
CONJUGATED TOXIN->TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
Mediator Substance Details
none
SELECTIVE
Ki
Created by admin on Fri Jul 10 18:38:03 EDT 2020 , Edited by admin on Fri Jul 10 18:38:03 EDT 2020
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
RADIOLIGAND->TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
CONJUGATED TOXIN->TARGET
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
LIGAND->TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
Mediator Substance Details
none
IC50
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
Mediator Substance Details
none
IRREVERSIBLE INHIBITOR
IC50
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
ANTIGEN->TARGET
Mediator Substance Details
none
Identified as a definitive diagnostic marker, key driver and therapeutic target for chordoma, a malignant tumor that arises from remnant notochordal cells lodged in the vertebrae
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
CONJUGATED TOXIN->TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
ANTIGEN->TARGET
none
Mediator Substance Details
none
Created by admin on Sat Jul 11 04:30:10 EDT 2020 , Edited by admin on Sat Jul 11 04:30:10 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
ANTIGEN->TARGET
none
Mediator Substance Details
none
T-CELL ANTIGEN
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
CONJUGATED TOXIN->TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
RADIOLIGAND->TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
LIGAND->TARGET
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 22:56:11 EDT 2020 , Edited by admin on Fri Jul 10 22:56:11 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
VACCINE ANTIGEN->TARGET
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Fri Jul 10 17:55:44 EDT 2020 , Edited by admin on Fri Jul 10 17:55:44 EDT 2020
Structural Modifications
Modification Type Location Site Location Type Residue Modified Extent Modification Name Modification ID
AMINO ACID SUBSTITUTION [1_1117] [1_1174] [1_1226] TYROSINE TYROSINE O-PHOSPHATE 2R86C98KDX
AMINO ACID SUBSTITUTION [1_1032] [1_1056] [1_1061] [1_1085] [1_1129] SERINE DEXFOSFOSERINE VI4F0K069V
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT CHEMICAL 0
Created Fri Jul 10 17:55:44 EDT 2020
Created By admin
Last Edited Fri Jul 10 17:55:44 EDT 2020
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File
1 https://en.wikipedia.org/wiki/Brachyury WIKI
2 MOL CANCER THER. 2012 MAR;11(3):582-93 JOURNAL ARTICLE NOMEN
3 FDA-SRS SRS NOMEN
4 P122 INN PUBLIC_DOMAIN_RELEASE
5 dump-public-2020-07-07.gsrs BATCH_IMPORT Fri Jul 10 17:55:44 EDT 2020
6 https://en.wikipedia.org/wiki/Pertuzumab WEBSITE NOMEN
7 STN STN (SCIFINDER) NOMEN
8 NK-92/5.28.z Cells CLINICAL_TRIALS.GOV
9 Generated from relationship on:'PERTUZUMAB' SYSTEM
10 Kim, Tae-Yong, et al. "A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer." Gastric Cancer (2019): 1-9. JA CLIN NOMEN POT
11 UNIPROT UNIPROT NOMEN
12 https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1578 NCI THESAURUS
13 Wei, Hudie, et al. "Structural basis of a novel heterodimeric Fc for bispecific antibody production." Oncotarget 8.31 (2017): 51037. JA PUBLIC_DOMAIN_RELEASE
14 SRS import [7J9Y28299R] SRS NOMEN Fri Apr 28 15:36:45 EDT 2017
15 STN STN (SCIFINDER)
16 ZW49 WEB PAGE
17 Ad5 [E1-, E2b-]-HER2/Neu vaccine ETBX-021 NCI DRUG DICTIONARY PUBLIC_DOMAIN_RELEASE
18 Kim, Eunyoung, et al. "Metabolite identification of a new tyrosine kinase inhibitor, HM781€?36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry." Rapid Communications in Mass Spectrometry 27.11 (2013): 1183-1195. JA NOMEN PUBLIC_DOMAIN_RELEASE
19 NCI THESAURUS NCI THESAURUS NOMEN PUBLIC_DOMAIN_RELEASE
20 Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans Lisa J. Christopher, Haizheng Hong, Blisse J. Vakkalagadda, Pamela L. Clemens, Hong Su, Vikram Roongta, Alban Allentoff, Haojun Sun, Kevin Heller, Christopher T. Harbison, Ramaswamy A. Iyer, William G. Humphreys, Tai Wong and Steven Zhang Drug Metabolism and Disposition November 2010, 38 (11) 2049-2059; DOI: https://doi.org/10.1124/dmd.110.034850 JA PUBLIC_DOMAIN_RELEASE
21 X. Li et al. / European Journal of Pharmaceutical Sciences 110 (2017) 51€“61 JA PUBLIC_DOMAIN_RELEASE
22 BDTX 189 WEB PAGE
23 BDTX 189 WEB PAGE
24 http://www.arraybiopharma.com/files/4113/9810/7987/PubAttachment506.pdf MEETING ABSTRACT NOMEN
25 http://www.uniprot.org/uniprot/P04626 SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
26 ZW49 WEB PAGE
27 DOI: 10.18632/ONCOTARGET.11751 JOURNAL ARTICLE NOMEN
28 Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans Lisa J. Christopher, Haizheng Hong, Blisse J. Vakkalagadda, Pamela L. Clemens, Hong Su, Vikram Roongta, Alban Allentoff, Haojun Sun, Kevin Heller, Christopher T. Harbison, Ramaswamy A. Iyer, William G. Humphreys, Tai Wong and Steven Zhang Drug Metabolism and Disposition November 2010, 38 (11) 2049-2059; DOI: https://doi.org/10.1124/dmd.110.034850 JA PUBLIC_DOMAIN_RELEASE
29 Holmes, Jarrod P., et al. "Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine." Journal of Clinical Oncology 26.20 (2008): 3426-3433. JA PUBLIC_DOMAIN_RELEASE
30 https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C102535 NCI THESAURUS NOMEN PUBLIC_DOMAIN_RELEASE
31 Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor JA
32 Hamblett, Kevin J., et al. "ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers." (2018): 3914-3914. MEETING ABSTRACT POT
33 STN STN (SCIFINDER)
34 USAN COUN 2005 USANCOUN NOMEN PUBLIC_DOMAIN_RELEASE
35 Generated from relationship on:'MM-111' SYSTEM
36 https://adisinsight.springer.com/drugs/800029938 WEB PAGE NOMEN
37 https://www.ncbi.nlm.nih.gov/pubmed/22248472 SRS NOMEN
38 Generated from relationship on:'TUCATINIB' SYSTEM
39 Generated from relationship on:'GP-2 HER2-DERIVED, HLA-A2+ RESTRICTED PEPTIDE' SYSTEM
40 Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans Lisa J. Christopher, Haizheng Hong, Blisse J. Vakkalagadda, Pamela L. Clemens, Hong Su, Vikram Roongta, Alban Allentoff, Haojun Sun, Kevin Heller, Christopher T. Harbison, Ramaswamy A. Iyer, William G. Humphreys, Tai Wong and Steven Zhang Drug Metabolism and Disposition November 2010, 38 (11) 2049-2059; DOI: https://doi.org/10.1124/dmd.110.034850 JA PUBLIC_DOMAIN_RELEASE
41 Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans Lisa J. Christopher, Haizheng Hong, Blisse J. Vakkalagadda, Pamela L. Clemens, Hong Su, Vikram Roongta, Alban Allentoff, Haojun Sun, Kevin Heller, Christopher T. Harbison, Ramaswamy A. Iyer, William G. Humphreys, Tai Wong and Steven Zhang Drug Metabolism and Disposition November 2010, 38 (11) 2049-2059; DOI: https://doi.org/10.1124/dmd.110.034850 JA PUBLIC_DOMAIN_RELEASE
42 WIKIPEDIA WIKI NOMEN PUBLIC_DOMAIN_RELEASE
43 SRS CODE IMPORT SRS NOMEN Fri Apr 28 15:36:45 EDT 2017

Version

Version Comments

Editor

Change Date

86
admin
Sat Jul 11 00:30:10 EDT 2020
85
admin
Fri Jul 10 18:56:11 EDT 2020
84
admin
Fri Jul 10 14:38:03 EDT 2020
83
admin
Fri Jul 10 14:35:32 EDT 2020